RxDoctor Payments Data

Courtney Albers, APRN

Psychiatric/Mental Health · Shively, KYNPI 1104535517

Payments from drug & device makers

$2,734in general payments, 2019–2025

Across 33 payments — averaging $82.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$438
  • Axsome Therapeutics, Inc.$392
  • AbbVie$352
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$306
  • Alkermes, Inc.$248
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$197
  • plus $801 from 8 others

What the payments were for

  • Food & beverage$2,734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,734 in reported general payments places this provider in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$6,533
Medicare patients
31
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$182,722
Invega SustennaPaliperidone Palmitate28$86,130
VraylarCariprazine Hcl15$31,401
Chlorpromazine Hcl18$10,648
TrintellixVortioxetine Hydrobromide11$7,594
Ziprasidone Hcl47$6,156
Lurasidone Hcl23$4,224
Aripiprazole43$3,863
Quetiapine Fumarate74$1,512
Divalproex Sodium50$1,293
Olanzapine28$1,084
Bupropion XlBupropion Hcl70$1,070
Vilazodone Hcl17$996
Haloperidol38$927
Clozapine14$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$95$182,72225 claims
Johnson & JohnsonInvega Sustenna$438$86,13028 claims
AbbVieVraylar$352$31,40115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Shively

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →